Bristol-Myers Squibb Company (BMY)
| Market Cap | 101.55B |
| Revenue (ttm) | 47.64B |
| Net Income (ttm) | 5.42B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.67 |
| PE Ratio | 18.68 |
| Forward PE | 7.56 |
| Dividend | $2.48 (4.97%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 1,418,250 |
| Open | 50.53 |
| Previous Close | 50.57 |
| Day's Range | 49.79 - 50.53 |
| 52-Week Range | 39.35 - 63.33 |
| Beta | 0.40 |
| Analysts | Hold |
| Price Target | 58.93 (+18.1%) |
| Earnings Date | Apr 24, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $58.93, which is an increase of 18.10% from the latest price.
News
Top 3 Health Care Stocks That May Rocket Higher In April
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Retirement Strategy: 2 Blue Chip Dividends Now Way Too Cheap
Earnings season offers opportunities to buy undervalued blue-chip stocks like Verizon and Bristol Myers Squibb, both yielding 5-7% and trading below historical PE ratios. Verizon's growth in 5G, broad...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
5 Positives From Bristol-Myers Squibb's Q1 2025 Results
Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised posit...
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry'...
Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance
Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth port...
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Thursday.
Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Chuck Triano - SVP and Head of IR Chris Boerner - Board Chair and CEO David Elk...
Bristol-Myers Squibb Is A Good Pick
Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter, Bristol-Myers...
Bristol-Myers Q1 Earnings Review: A Decidedly Mixed Bag - Rating Downgrade
Bristol-Myers Squibb Company's Q1 2025 earnings show a 6% YoY revenue decline but improved EPS, with upgraded full-year guidance and a strong dividend yield of over 5%. BMY's growth portfolio is neari...
Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance
Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales
Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system...
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
Bristol Myers Squibb beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs. The company said its guidance revisions include the estimated imp...
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2025.
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers Squibb & Co BMY on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatme...
Bristol Myers Stock Falls After Drug Trial Setback. Why 1 Analyst Isn't Worried.
Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.
Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophrenia
Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference compared to a placebo in a late-stage trial studying it as a add-on treatment for schizophre...
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ARISE--BMS Announces Topline Results from Phase 3 ARISE Trial.
Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession
Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. BMY stock has a history of outperformance during recessions and bear markets on Wall Street. Relative total retur...
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications.
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seve...
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
Bristol Myers Squibb & Co BMY on Monday announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive...
Bristol Myers' heart disease drug fails to meet main goals in late-stage study
Bristol Myers Squibb said on Monday its experimental drug to treat a type of heart disease did not meet the main goals in a late-stage study.